- Takeda Pharmaceutical Company Limited (NYSE:TAK) reported a fiscal 2021 core net profit of ¥663.7 billion, an increase of 1.3% from the prior year. Core earnings per share reached ¥425, up 1.2%.
- FY21 net profit declined 38.8% to ¥230.1 billion.
- Fiscal 2021 core revenue was ¥3.42 trillion, an underlying increase of 7.4%.
- Gastroenterology sales reached ¥875.7 billion, up 7% on an underlying basis driven by gut-selective Entyvio and anti-acid therapy Takecab. Takeda is no longer expecting entry of biosimilars upon loss of data exclusivity.
- Also See: Takeda's Maribavir Reduces Hospitalization Rates, Hospital Stay In Post-Transplant Infection Patients.
- Rare Diseases sales decreased 1% to ¥611.2 billion in reported revenue, impacted by a decline in line with expectations in Rare Hematology due to intensified competition.
- Plasma Derived Therapy Immunology segment revenues increased 14% to ¥507.0 billion, and Oncology sales grew 8% to ¥468.7 billion.
- Neuroscience sales were up 10% to ¥482.3 billion.
- Guidance: Takeda forecasts FY22 core sales of ¥3.69 trillion, up 7.9%.
- In FY2022, Takeda expects continued revenue growth. Core operating profit is expected to reach ¥1.1 trillion, mainly driven by business momentum.
- Price Action: TAK shares closed 1.33% higher at $14.52 on Tuesday.
